Pharmaceutical Preparations · DE · CIK 1426800
Developing innovative therapeutics targeting serious viral diseases like herpes, hepatitis delta, and hepatitis B
Comparable business profile · signals at a glance
In the 90 days to Mar 30, 2026: 2 sold $14K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 30, 2026 | Bjorkquist Jeanette MPFO and PAO | Sell | 312 | $26.65 | $8K |
| Mar 30, 2026 | White Nicole SChief Manufacturing Officer | Sell | 188 | $26.65 | $5K |
| Mar 30, 2026 | Bjorkquist Jeanette MPFO and PAO | Sell | 16 | $27.49 | $440 |
| Mar 30, 2026 | White Nicole SChief Manufacturing Officer | Sell | 9 | $27.49 | $247 |
| Aug 8, 2025 | Gilead Sciences, Inc.TenPercentOwner | Buy | 2,295,920 | — | — |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.